A dose-escalation and dose expansion Phase I clinical study of HQP1351 in patients with Chronic myeloid leukaemia (CML)
Phase of Trial: Phase I
Latest Information Update: 04 Dec 2018
At a glance
- Drugs HQP 1351 (Primary)
- Indications Chronic myeloid leukaemia
- Focus Adverse reactions; Therapeutic Use
- 04 Dec 2018 Preliminary results assessing safety and efficacy of HQP1351 in patients with chronic myeloid leukemia, presented at the 60th Annual Meeting and Exposition of the American Society of Hematology.
- 03 Dec 2018 According to an Ascentage Pharma media release, data from this study were presented at the 60th American Society of Hematology Annual Meeting.
- 03 Dec 2018 Results presented in an Ascentage Pharma media release.